Journal of Clinical Oncology · 2005 · 38 citations · 0 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyHepatic PharmacokineticsPharmacokinetics Of Anticancer AgentsHepatic ToxicityHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyPharmacokinetics In Liver DiseasePharmacokinetics Of Anticancer DrugsTyrosine Kinase InhibitorsHepatocellular Carcinoma TreatmentTotal Serum BilirubinTyrosine Kinase InhibitionTyrosine Kinase Inhibitor TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
4134 Background: The expression of vascular endothelial growth factors (VEGFs) and VEGF receptors are associated with progression of hepatocellular carcinoma (HCC). PTK787/ZK 222584 (PTK/ZK) is a novel, oral, anti-angiogenesis compound that blocks tyrosine kinase signaling from all known VEGF receptors. Methods: This was an open-label, multi-center, phase I study to characterize the safety, tolerability, and pharmacokinetic (PK) profile of PTK/ZK, administered once daily at a dose of 750 mg or 1250 mg in adults with unresectable HCC. Pts previously treated with surgery, chemotherapy or radiotherapy were eligible. Pts were stratified into three groups based on total bilirubin and AST/ALT levels. Pts in Group 1, 2, 3 had mild, moderate and severe hepatic dysfunction respectively. PK data were collected from all Pts on days 1, 28, and 56. The primary endpoints were safety, tolerability of PTK/ZK, and the effects of hepatic dysfunction on the PK of PTK/ZK. Results: 34 Pts were enrolled, 21 in Group 1; 8 in group 2; and 5 in group 3. In all groups the most frequently reported adverse events (AEs) were vomiting, nausea, diarrhea, fatigue, anorexia and dizziness. A correlation between these AEs and the study drug dose was not observed. In Group 1, 2 of 4 Pts who received the 1250mg/d dose experienced DLTs (CTC grade 3 fatigue & CTC grade 4 elevation of AST). Two of the 6 Pts who received the 1000 mg/d dose experienced DLTs (ALT over 1.5X baseline and fatal hepatic tumor hemorrhage). No DLTs were observed at the 750mg/d dose, defined as the maximal tolerated dose (MTD) in Pts who have mild hepatic impairment. It was decided not to escalate above 750 mg/d in the other two groups. PK analysis indicated that there was no accumulation of PTK/ZK. Biologically active levels of PTK/ZK can be reached at a dosage of 750 mg/d. TTP in Pts who completed the trial ranged from 42 to 415 days. Of Pts in all groups,18 were evaluable for tumor response. No CR or PR was observed. 9 Pts had a best response of stable disease and 9 had progressive disease. Conclusion: 750 mg/d PTK/ZK is well tolerated in Pts with HCC and various degrees of hepatic impairment. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Jenapharm, Novartis, Schering AG